A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.
|Videos|November 10, 2022
Institutional Perspectives in Neurology, Chaired by Robert T. Naismith, MD
Author(s)NeurologyLive® Staff
Chaired by Robert T. Naismith, MD, of Washington University in St. Louis, the presentations also feature Salim Chahin, MD, MSCE; Anne H. Cross, MD; Gregory F. Wu, MD, PhD; and Matthew R. Brier, MD, PhD. [WATCH TIME: 1 hour, 55 minutes]
Advertisement
NeurologyLive® State of the Science events are short meetings designed to educate neurologists and APPs on the clinical benefits associated with the new science driving new thinking. Our renowned faculty focuses on the most relevant topics to ultimately improve patient care.
TOPICS INCLUDE:
- 02:45 – ECTRIMS Case Presentation: Evidence-Based MS Care — Robert T. Naismith, MD
- 17:25 – Pro: Epstein-Barr Virus Causes Multiple Sclerosis — Anne H. Cross, MD
- 38:30 – Con: Epstein-Barr Virus Causes Multiple Sclerosis — Gregory F. Wu, MD, PhD
- 56:20 – Question & Answer
- 1:08:10 – Choosing a DMT — Salim Chahin, MD, MSCE
- 1:23:55 – Clinical Neuroimaging in MS: More Than Counting Lesions — Matthew R. Brier, MD, PhD
- 1:39:55 – Question & Answer
Advertisement
Related to this article
The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.
Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.
Open-label extension data showed that disability trends observed with vidofludimus calcium during the double-blind period of the phase 2 CALLIPER trial persisted with continued treatment in progressive MS.
Early phase 1 data in 3 patients suggest CTA313, an allogeneic CD19/BCMA CAR-T, may stabilize disability with a manageable safety profile in progressive MS.
One-year data from the phase 3 AQUARELLE study found that divozilimab, an anti-CD20 antibody, reduced relapse risk in patients with neuromyelitis optica spectrum disorder.
Findings from the phase 3 METEOROID trial showed that satralizumab reduced the risk of relapse in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease.
A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral hemorrhage reduced recurrent stroke risk.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated
2
Clene Submits NDA Seeking Accelerated Approval for ALS Drug
3
Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis
4
FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia
5